American Society of Hirudotherapy

Neuropeptide-derived antimicrobial peptides from invertebrates for biomedical applications

Review published in Curr Med Chem (2005)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewAntimicrobial ResistanceSalivary PharmacologyDrug DevelopmentSalzet M et al. · Current medicinal chemistry, 2005

Abstract

Since the beginning of the 20th century, important medicinal progress has led medical doctors to think that the end of devastating epidemics has arrived. In 1930, the discovery of sulfamides and penicillin opened a wide area of applications able to fight against bacterial infections. However, almost all antibiotics were baffled by the great ability to adaptation of bacteria (1) and the emergence of new bacterial agents, discovered with up-dated technologies. The living world is perpetually in co-evolution and since more than 3 billion years, bacteria have developed resistance mechanisms to overcome external aggressions. Thus, in the middle of the 80th century, multi-resistant bacteria appeared and disseminated out from hospitals. In this context, researches have been developed in order to find new antimicrobial substances to destroy such new types of bacteria. Thus, several groups have turned their focus on invertebrates, which co-evoluad with human and have appeared on the planet since a long time. Evidence of new families of antimicrobial substances isolated from invertebrates different to the classical cationic peptide family i.e. dipeptides and anionic peptides been given. Moreover, these molecules are also present in human and may serve in the innate immune response as an important survival strategy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tReview
Indexed MeSH termsAnimalsAnti-Bacterial AgentsCardiovascular DiseasesHumansImmunity, InnateInvertebratesLarvaLeechesNeuropeptidesPeptides

Summary

Review of invertebrate-derived antimicrobial peptides including leech AMPs for biomedical use against multi-resistant bacteria. Surveys neuropeptide-derived families with potential therapeutic applications.

Why This Matters for Hirudotherapy

This review discusses the search for new antimicrobial substances from invertebrates in the context of rising multidrug-resistant bacteria. It describes evidence of new families of antimicrobial substances isolated from invertebrates—including dipeptides and anionic peptides, distinct from classical cationic peptides—and notes these molecules may participate in innate immune response and are also present in humans. The abstract does not mention leeches, leech secretome components, neuropeptide-derived peptides, or hirudotherapy. Consequently, there is no defensible leech-specific relevance in this article's abstract, and any link to ASH's domain cannot be substantiated from the text provided. The article offers general background on invertebrate-derived antimicrobials without original leech-related data.

Citation

Neuropeptide-derived antimicrobial peptides from invertebrates for biomedical applications.

Salzet M et al. · Current medicinal chemistry, 2005

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.